Acasă › Tumori cerebrale › Massachusetts › Boston
Studii clinice pentru Tumori cerebrale în Boston, MA
28 studii pentru Tumori cerebrale caută participanți în și în jurul orașului Boston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
În curs de recrutareFaza 1/2
- Tufts Medical Center, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
În curs de recrutareFaza 2
- Local Institution - 0124, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
În curs de recrutare
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
În curs de recrutareFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
Targeted Pediatric High-Grade Glioma Therapy
În curs de recrutareStudiu observațional
- Dana-Farber Cancer Institute, Boston
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
În curs de recrutareFaza 2
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
În curs de recrutareFaza 2
- Brigham and Women's Hospital, Boston
B7-H3.CD28Z.CART in CNS Neoplasms
În curs de recrutareFaza 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
În curs de recrutareFaza 2
- Susan Chi, Boston
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
În curs de recrutare
- Massachusetts General Hospital, Boston
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
În curs de recrutareStudiu observațional
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Palbociclib and Pembrolizumab In Central Nervous System Metastases
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
În curs de recrutareFaza 3
- Tufts Medical Center, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
În curs de recrutareFaza 2
- Dana-Farber Cancer Institute, Boston
NTS-WBRT in Brain Metastases
În curs de recrutareFaza 2
- Massachusetts General Hospital Cancer Center, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
În curs de recrutare
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
În curs de recrutare
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
În curs de recrutareFaza 1 timpurie
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
În curs de recrutareFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
ASCENT Intervention for Brain Tumor Patients
În curs de recrutare
- Massachusetts General Hospital Cancer Center, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
În curs de recrutareStudiu observațional
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
În curs de recrutareStudiu observațional
- Massachusetts General Hospital, Boston
Studii pentru Tumori cerebrale în alte orașe
- Houston, TX35 studii
- New York City, NY25 studii
- Washington, DC20 studii
- Los Angeles, CA16 studii
- Miami, FL15 studii
- Durham, NC14 studii
- St. Louis, MO12 studii
- Cleveland, OH11 studii
- Seattle, WA11 studii
- Rochester, MN11 studii
- Baltimore, MD11 studii
- Columbus, OH11 studii
Alte studii în Boston
- Cancer de sân111 studii
- Cancer pulmonar cu celule non-pătrate90 studii
- Cancer (toate tipurile)86 studii
- Cancer colorectal63 studii
- Cancer metastatic63 studii
- Cancer pulmonar62 studii
- Cancer ovarian61 studii
- Cancer de prostată59 studii
- Depresie52 studii
- Cancer endometrial50 studii
- Insuficiență cardiacă44 studii
- Leucemie mieloasă acută44 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.